Ascentage Pharma Group International Announces Trustee Purchase of Shares for 2022 RSU Scheme
Key Points for Investors
- Significant On-Market Share Purchase: On June 11, 2026, the Trustee of Ascentage Pharma Group International purchased 110,000 existing shares on the open market, specifically to satisfy future vesting of Restricted Share Units (RSUs) under the company’s 2022 RSU Scheme.
- Purchase Details:
- Total consideration paid (excluding related expenses): HK\$3,671,094
- Average price per share: Approximately HK\$33.37
- Newly purchased shares represent 0.0294% of the total shares issued as of this announcement date
- Aggregate Holdings: After this transaction, the Trustee holds 2,615,000 shares for the 2022 RSU Scheme.
- Purpose: These shares are reserved solely for delivering to participants as their RSUs vest, aligning management and employee incentives with shareholder interests.
- Governance: The Trustee will not exercise voting rights attached to these shares while they are held in trust.
- No New RSU Grants: The only RSU awards granted under the 2022 scheme to date are those on June 23, 2022 (initial grant), and further grants on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025, and April 20, 2026.
Board Composition
As of June 11, 2026, the Board is comprised of:
- Dr. Yang Dajun (Chairman and Executive Director)
- Dr. Wang Shaomeng (Non-Executive Director)
- Dr. Lu Simon Dazhong (Non-Executive Director, also meets the independence requirements of the U.S. SEC and Nasdaq)
- Mr. Ye Changqing (Independent Non-Executive Director)
- Mr. Ren Wei (Independent Non-Executive Director)
- Dr. David Sidransky (Lead Independent Non-Executive Director)
- Ms. Marina S. Bozilenko (Independent Non-Executive Director)
- Dr. Debra Yu (Independent Non-Executive Director)
- Dr. Marc E. Lippman, MD (Independent Non-Executive Director)
Potential Price Sensitivity and Shareholder Considerations
- Share Buybacks/Trustee Purchases: This on-market purchase may signal management’s confidence in the company’s future and could be interpreted as supporting the current share price.
- Impact on Supply: The purchased shares are held in trust and are not available for trading, potentially reducing float and adding upward price pressure.
- Incentive Alignment: The RSU scheme incentivizes key employees and aligns their interests with those of shareholders, which is often viewed positively by the market.
Conclusion
The company’s ongoing commitment to its 2022 RSU Scheme, evidenced by the purchase of shares for future vesting, may be a positive sign for investors, reflecting both management’s confidence and ongoing efforts to retain and motivate key personnel. This action could be price sensitive as it demonstrates the company’s willingness to support its share price and manage supply in the open market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult professional advisors before making investment decisions. The author and publisher shall not be liable for any losses arising from reliance on this information.
亞盛醫藥集團國際公佈信託人為2022年RSU計劃購入股份
投資者重點
- 重大市場購股： 於2026年6月11日，亞盛醫藥的信託人於公開市場購入110,000股現有股份，專為滿足2022年限制性股票單位（RSU）計劃下未來歸屬所需。
- 購股詳情：
- 總代價（不包括相關費用）：港幣3,671,094元
- 平均每股代價：約港幣33.37元
- 佔截至公告日發行股份總數比例：約0.0294%
- 累計持股： 此次交易後，信託人合共持有2,615,000股作為2022年RSU計劃用途。
- 用途： 這些股份僅用作向RSU參與者於歸屬時交付，確保管理層及員工利益與股東一致。
- 公司治理： 信託人持有期間，該等股份不會被行使投票權。
- 未有新RSU授出： 2022計劃下現時僅有於2022年6月23日（首次授出）、2023年5月4日、2024年9月2日、2025年6月27日、2025年11月26日及2026年4月20日的進一步授出。
董事會成員
截至2026年6月11日，董事會成員包括：
- 楊大俊博士（主席兼執行董事）
- 王少萌博士（非執行董事）
- 呂大中博士（非執行董事，亦符合美國SEC及納斯達克獨立性規定）
- 葉長青先生（獨立非執行董事）
- 任偉先生（獨立非執行董事）
- David Sidransky博士（首席獨立非執行董事）
- Marina S. Bozilenko女士（獨立非執行董事）
- 虞德麗博士（獨立非執行董事）
- Marc E. Lippman, MD博士（獨立非執行董事）
對股價敏感及股東需知事項
- 市場購股信號： 此次市場購股動作，可能被解讀為管理層對公司前景有信心，有助支持現有股價。
- 供應影響： 被購入的股份由信託人持有，不會在市場流通，有機會減少流通量，對股價有正面推動。
- 激勵機制： RSU計劃有助激勵關鍵員工，提升與股東利益一致性，市場一般持正面看法。
總結
公司持續推進2022年RSU計劃，並為未來歸屬提前購入股份，反映管理層對公司發展有信心，有助員工保留及激勵。此舉或具股價敏感性，顯示公司有意支持股價及管理市場供應。
免責聲明：本文僅供資訊參考，並不構成任何投資建議。投資者應自行進行盡職調查並咨詢專業顧問，方作出投資決定。作者及出版方對因依賴此資訊而造成的任何損失概不負責。
